Aardvark Therapeutics, Inc.
Clinical trials sponsored by Aardvark Therapeutics, Inc., explained in plain language.
-
New hope for rare hunger disorder: 12-Month drug trial launches
Disease control TerminatedThis study tests whether a daily medication called ARD-101 can safely reduce the intense, constant hunger (hyperphagia) that people with Prader-Willi syndrome experience. About 90 participants who completed a prior study will take the drug for up to 12 months. Researchers will tr…
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for rare hunger disorder: ARD-101 trial launches
Symptom relief TerminatedThis study tests whether ARD-101 can reduce the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 90 participants will take either the drug or a placebo daily for 12 weeks. Caregivers will track changes in hunger-related behaviors using a questionnaire. …
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC